communityacquir
pneumonia
cap
common
ill
major
patient
treat
hospit
yet
greatest
burden
cost
care
come
inpati
manag
past
sever
year
manag
patient
advanc
new
inform
natur
histori
prognosi
ill
util
serum
marker
guid
manag
use
appropri
clinic
tool
guid
siteofcar
decis
find
guidelin
develop
way
improv
patient
outcom
challeng
patient
manag
includ
emerg
new
pathogen
progress
antibiot
resist
common
pathogen
streptococcu
pneumonia
new
antimicrobi
treatment
option
avail
util
new
therapi
limit
drugrel
toxic
ancillari
care
sever
pneumonia
activ
protein
c
corticosteroid
studi
recent
inpati
care
affect
develop
evidencebas
core
measur
manag
promot
center
medicar
medicaid
servic
form
basi
public
report
hospit
perform
cap
care
abbrevi
apach
acut
physiolog
chronic
health
evalu
cap
communityacquir
pneumonia
cm
center
medicar
medicaid
servic
crp
creactiv
protein
confus
elev
bun
level
elev
respiratori
rate
low
systol
diastol
bp
age
year
age
drsp
drugresist
streptococcu
pneumonia
hcap
healthcareassoci
pneumonia
mrsa
methicillinresist
staphylococcu
aureu
odd
ratio
pct
procalcitonin
psi
pneumonia
sever
index
sar
sever
acut
respiratori
syndrom
n
past
sever
year
clinic
advanc
communityacquir
pneumonia
cap
emerg
number
area
aid
care
inpati
outpati
major
clinic
issu
cap
patient
chang
spectrum
etiolog
includ
drugresist
streptococcu
pneumonia
drsp
methicillinresist
staphylococcu
aureu
mrsa
emerg
viral
pathogen
eg
sever
acut
respiratori
syndrom
sar
avian
influenza
addit
interest
better
understand
natur
histori
prognosi
cap
tri
defin
role
prognost
score
system
guid
decis
site
care
ie
inpati
outpati
icu
appli
number
serum
marker
ie
creactiv
protein
crp
procalcitonin
pct
prognost
outcom
new
antimicrobi
agent
becom
avail
outpati
inpati
sever
antibiot
class
util
agent
limit
new
find
toxic
evid
registr
trial
medic
ie
gatifloxacin
telithromycin
prior
approv
clinic
use
addit
new
antimicrobi
agent
paradigm
therapi
advanc
focu
better
defin
optim
durat
therapi
role
adjunct
therapi
sever
ill
includ
corticosteroid
activ
protein
c
one
major
factor
domin
inpati
care
cap
unit
state
promulg
core
measur
standard
care
support
center
medicar
medicaid
servic
cm
joint
commiss
accredit
healthcar
organ
success
achiev
measur
publicli
report
perform
individu
hospit
seem
possibl
data
could
serv
futur
basi
pay
perform
therebi
impact
financi
wellb
specif
healthcar
institut
interest
core
measur
refocus
attent
assur
patient
receiv
evidencebas
antibiot
choic
receiv
time
administr
antibiot
proper
use
blood
cultur
prior
antibiot
administr
patient
current
pneumococc
influenza
vaccin
studi
cap
examin
shortterm
outcom
ill
focus
either
inpati
mortal
kaplan
colleagu
use
medicar
databas
perform
match
casecontrol
studi
evalu
longterm
impact
ie
mortal
rate
older
patient
cap
author
compar
cap
patient
hospit
control
subject
patient
match
age
sex
race
inhospit
mortal
rate
cap
patient
exceed
control
subject
vs
respect
differ
mortal
rate
even
dramat
vs
respect
fig
high
mortal
rate
impress
differ
could
explain
type
underli
diseas
find
persist
even
hospit
survivor
examin
find
make
clear
cap
much
selflimit
ill
surviv
mortal
rate
elderli
patient
cap
four
time
higher
inhospit
mortal
rate
one
three
survivor
cap
die
subsequ
year
follow
hospit
discharg
exact
caus
death
examin
studi
popul
gener
elderli
year
age
nurs
home
patient
includ
comorbid
medic
ill
find
expand
older
scandinavian
studi
report
lower
surviv
rate
cap
patient
year
age
agematch
popul
without
cap
studi
rel
risk
death
cap
patient
compar
without
cap
surviv
rate
compar
noncap
popul
mani
death
relat
cardiovascular
diseas
subsequ
pneumonia
data
make
clear
cap
requir
hospit
admiss
diseas
prevent
whenev
possibl
elderli
optim
manag
cap
requir
prompt
recognit
serious
ill
patient
avoid
mistak
failur
use
hospit
icu
patient
could
benefit
care
observ
set
hand
major
impact
cost
cap
care
determin
casecontrol
studi
medicar
patient
cap
five
control
subject
match
age
sex
race
case
inhospit
mortal
rate
patient
cap
significantli
higher
control
subject
kaplan
et
al
whether
patient
admit
hospit
unit
state
cap
patient
admit
hospit
dollar
spent
patient
account
total
cost
care
diseas
emphas
impact
hospit
admiss
decis
number
year
prognost
score
system
use
defin
predict
mortal
rate
cap
also
infer
site
care
reserv
hospit
admiss
high
predict
mortal
rate
two
commonli
use
tool
purpos
predict
outcom
cap
patient
pneumonia
sever
index
psi
develop
unit
state
british
thorac
societi
rule
recent
modifi
refer
assess
follow
five
factor
confus
elev
bun
level
elev
respiratori
rate
low
systol
diastol
bp
age
year
age
rule
approach
limit
may
best
view
complementari
ideal
identifi
patient
opposit
end
diseas
spectrum
psi
best
valid
way
identifi
patient
low
risk
mortal
score
system
occasion
underestim
sever
ill
especi
young
patient
without
comorbid
ill
heavili
weight
age
comorbid
measur
capspecif
diseas
sever
hand
approach
may
ideal
identifi
patient
high
risk
mortal
sever
ill
due
cap
might
otherwis
overlook
without
formal
assess
subtl
aberr
key
vital
sign
howev
one
defici
approach
gener
account
comorbid
ill
thu
may
easili
appli
older
patient
may
still
substanti
mortal
risk
even
mild
form
cap
destabil
chronic
compens
diseas
process
one
recent
studi
compar
psi
patient
seen
emerg
depart
determin
good
predict
mortal
identifi
patient
low
risk
mortal
howev
psi
appear
discrimin
identifi
patient
low
risk
mortal
defin
psi
low
risk
class
iii
mortal
rate
defin
low
risk
score
mortal
rate
howev
may
valuabl
sever
diseas
end
spectrum
defin
highrisk
patient
score
progress
increas
risk
death
psi
less
discrimin
defin
two
group
sever
ill
anoth
analysi
score
also
appear
identifi
accur
patient
cap
like
benefit
treatment
drotrecogin
alfa
recombin
human
activ
protein
c
worldwid
evalu
sever
sepsi
prowess
studi
reexamin
data
studi
demonstr
threshold
score
associ
decreas
mortal
rate
drotrecogin
alfatr
patient
compar
control
subject
p
vs
decreas
mortal
rate
treat
patient
psi
class
iv
v
compar
control
subject
p
capelastegui
colleagu
use
psi
approach
evalu
larg
number
inpati
outpati
cap
spain
observ
simpler
version
exclud
measur
bun
therefor
use
outpati
could
accur
predict
mortal
rate
need
mechan
ventil
extent
need
hospit
addit
criteria
correl
time
clinic
stabil
thu
higher
score
predict
longer
durat
iv
therapi
longer
length
hospit
stay
psi
also
work
well
predict
mortal
studi
psi
good
predict
mortal
neither
use
defin
site
care
without
consid
clinic
social
variabl
studi
public
hospit
unit
state
mani
indig
patient
show
psi
could
defin
need
hospit
admiss
patient
homeless
acut
intox
stabl
home
environ
allow
discharg
hospit
receiv
oral
antibiot
therapi
one
recent
commentari
suggest
made
combin
prognost
score
tool
recogn
neither
approach
stand
alon
lowrisk
patient
ie
psi
class
iii
score
manag
home
seriou
vital
sign
abnorm
case
psi
comorbid
case
absent
patient
social
factor
ill
unstabl
necessit
hospit
moderaterisk
patient
ie
score
psi
class
iv
v
probabl
admit
hospit
clinic
assess
use
separ
need
icu
care
like
becom
clinic
stabl
rapidli
would
requir
short
hospit
stay
two
serum
marker
wide
studi
purpos
crp
pct
gener
measur
use
correl
outcom
data
recent
collect
pct
excit
find
serial
measur
correl
outcom
may
also
use
guid
durat
therapi
crp
measur
one
studi
patient
cap
compar
healthi
control
subject
patient
suspect
pneumonia
confirm
clinic
followup
level
highest
pneumonia
howev
among
proven
cap
level
crp
correl
clinic
cours
median
level
higher
hospit
patient
outpati
vs
mgl
respect
p
find
might
part
explain
observ
crp
level
tend
higher
pneumococc
legionella
etiolog
viral
atyp
pathogen
pneumonia
possibl
bacteri
ill
sever
ill
thu
need
hospit
gener
crp
acutephas
reactant
synthes
liver
sensit
specif
infect
pct
pct
precursor
calcitonin
hormon
effect
valu
aris
serum
level
increas
sever
bacteri
infect
viral
ill
releas
pct
stimul
microbi
toxin
includ
lipopolysaccharid
cytokin
eg
tumor
necrosi
factor
cellmedi
immun
respons
level
attenu
virusinduc
cytokin
studi
patient
pct
measur
within
h
hospit
admiss
cap
level
correl
psi
score
higher
class
iii
v
class
ii
develop
complic
higher
empyema
mechan
ventil
septic
shock
level
also
increas
die
compar
interestingli
level
higher
patient
low
risk
mortal
ie
low
psi
bacteri
etiolog
cap
without
similar
find
appli
sever
cap
may
mean
low
level
outpati
could
indic
safe
withhold
antibiot
therapi
anoth
recent
studi
support
idea
use
serial
measur
pct
level
guid
need
antibiot
therapi
durat
studi
patient
random
receiv
either
standard
care
therapi
guid
serial
measur
level
pct
evalu
patient
first
seen
h
later
antibiot
withheld
day
patient
admit
hospit
make
primarili
inpati
studi
use
pct
level
patient
antibiot
withheld
compar
receiv
standard
care
use
pct
level
guid
therapi
led
significantli
shorter
durat
therapi
appli
patient
regardless
psi
class
importantli
outcom
similar
group
document
safeti
look
strategi
reduc
antibiot
usag
serial
measur
pct
also
use
defin
prognosi
patient
sever
cap
one
studi
patient
one
measur
perform
within
h
icu
admiss
level
pct
higher
posit
bacteriolog
result
neg
result
complic
eg
septic
shock
organ
dysfunct
death
without
bolster
find
investig
group
collect
serial
pct
level
icu
cap
patient
day
day
studi
survivor
decreas
pct
level
nonsurvivor
increas
day
numer
clinic
paramet
also
measur
well
serial
level
crp
multivari
predictor
mortal
relev
factor
follow
need
mechan
ventil
odd
ratio
presenc
multilobar
infiltr
increas
pct
level
worsen
multiorgan
failur
score
among
mechan
ventil
patient
pct
level
day
highli
predict
mortal
remain
elev
serial
measur
crp
predict
valu
studi
clinic
relev
drsp
continu
debat
recent
data
suggest
frequenc
form
drug
resist
may
stabil
declin
concern
still
remain
class
antibiot
use
data
doern
et
al
studi
pneumococc
respiratori
isol
us
center
observ
penicillin
resist
present
occur
increas
frequenc
found
isol
intermedi
sensit
highli
resist
penicillin
hand
macrolid
resist
increas
although
lowlevel
efflux
pumpmedi
trimethoprimsulfa
resist
declin
quinolon
resist
rate
low
isol
firststep
mutat
par
c
still
permit
antibiot
activ
howev
second
mutat
gyr
acquir
organ
could
becom
quinoloneresist
urg
caution
observ
trend
type
mutat
term
reliabl
choic
suspect
drsp
quinolon
remain
effect
ceftriaxon
remain
activ
agent
resist
rate
clinic
studi
ceftriaxon
reliabl
choic
even
drsp
present
among
cephalosporin
cefuroxim
reliabl
choic
sinc
patient
bacteremia
vitro
resist
agent
wors
outcom
organ
sensit
agent
one
clinic
factor
drive
pneumococc
resist
antibiot
use
new
data
shown
recent
therapi
within
past
month
risk
factor
pneumococc
resist
remark
studi
toronto
bacteri
network
evalu
data
patient
case
invas
pneumococc
infect
histori
antibiot
therapi
preced
month
ident
therapi
known
studi
recent
therapi
penicillin
macrolid
trimethoprimsulfa
quinolon
cephalosporin
associ
higher
frequenc
resist
agent
among
class
antibiot
one
greatest
effect
recent
therapi
subsequ
resist
ie
highest
effect
quinolon
latter
find
consist
case
report
lack
respons
quinolon
cap
patient
document
recent
quinolon
therapi
major
risk
factor
data
lend
support
idea
patientspecif
antibiot
rotat
cap
make
sure
among
accept
therapeut
altern
clinician
take
histori
recent
antibiot
use
choos
agent
differ
patient
recent
receiv
mrsa
alway
nosocomi
pathogen
common
caus
ventilatorassoci
pneumonia
past
sever
year
mrsa
report
caus
sporad
case
sever
cap
especi
follow
preced
viral
infect
pathogen
nosocomi
counterpart
differ
genet
makeup
differ
host
suscept
differ
virul
antibiot
sensit
communityacquir
strain
gener
belong
singl
pulsefield
gel
electrophoresi
type
usa
strain
addit
carri
gene
product
necrot
toxin
pantonvalentin
leukocidin
confer
resist
methicillin
carriag
type
iv
meca
gene
carri
staphylococc
chromosom
cassett
type
iv
sccmec
element
case
report
sever
necrot
pneumonia
gener
previous
healthi
individu
follow
viral
infect
document
influenza
ill
pneumonia
often
rapidli
progress
bilater
shock
cavit
lung
parenchyma
pleural
effus
organ
sensit
wide
rang
antibiot
includ
vancomycin
clindamycin
trimethoprimsulfa
gentamicin
variabl
sensit
quinolon
optim
therapi
yet
defin
one
case
seri
report
failur
vancomycin
alon
overcom
either
addit
clindamycin
use
linezolid
find
may
relat
fact
clindamycin
linezolid
inhibit
toxin
product
thu
success
therapi
may
requir
antibacteri
antitoxin
form
treatment
past
sever
year
renew
interest
epidem
viral
ill
emerg
sar
recent
concern
avian
influenza
experi
emphas
epidem
natur
ill
rapid
patienttopati
spread
case
sar
risk
healthcar
worker
evid
littl
known
frequenc
viral
infect
routin
cap
thu
spanish
studi
topic
interest
investig
evalu
patient
pair
serolog
respiratori
virus
set
cap
classifi
patient
pure
viral
mix
viral
bacteri
pneumococc
cap
virus
investig
includ
influenza
parainfluenza
respiratori
syncyti
viru
adenoviru
virus
detect
patient
half
patient
virus
pathogen
present
influenza
common
infect
present
patient
viral
infect
clinic
correl
pure
viral
pneumonia
compar
pneumococc
pneumonia
presenc
heart
failur
absenc
expector
pure
viral
pneumonia
patient
need
visit
icu
psi
class
iv
v
interestingli
despit
high
mortal
risk
patient
defin
psi
class
none
die
given
import
influenza
viral
respiratori
infect
gener
role
infect
predispos
patient
mrsa
cap
data
highlight
rel
common
occurr
import
viral
pneumonia
commun
bacteriolog
aspir
pneumonia
aris
commun
set
confus
exact
role
anaerob
uncertain
studi
patient
year
age
admit
icu
longterm
care
facil
presum
aspir
pneumonia
bacteriolog
infect
studi
use
protect
bal
fluid
sampl
collect
within
h
icu
admiss
aspir
presum
present
patient
known
risk
factor
intestin
swallow
disord
neurolog
diseas
anatom
abnorm
could
lead
aspir
data
demonstr
gramneg
pathogen
domin
type
pathogen
anaerob
present
patient
patient
anaerob
pathogen
present
fig
anoth
studi
lung
abscess
diseas
commonli
attribut
aspir
anaerob
infect
patient
evalu
uncontamin
specimen
includ
transthorac
needl
aspir
pleural
fluid
blood
cultur
specimen
surgic
sampl
bronchoscopi
sampl
alon
group
pure
anaerob
infect
present
patient
other
mix
infect
howev
aerob
gramneg
pathogen
present
patient
klebsiella
pneumonia
recov
patient
thu
level
involv
enter
gramneg
pathogen
two
aspirationrel
ill
quit
high
must
consid
select
therapi
guidelin
cap
stress
approach
empir
therapi
recogn
difficulti
obtain
pathogenspecif
data
allow
earli
focus
initi
therapi
choic
one
recent
studi
found
therapi
given
accord
guidelin
led
patient
becom
clinic
stabl
sooner
therapi
use
howev
valu
empir
therapi
evalu
directli
studi
netherland
use
prospect
random
open
studi
design
compar
empir
therapi
pathogendirect
therapi
patient
clinic
radiograph
proven
cap
patient
undergon
extens
diagnost
test
empir
therapi
group
receiv
therapi
inhibitor
combin
erythromycin
icu
ceftazidim
plu
erythromycin
icu
pathogendirect
group
gram
stain
perform
sputum
sampl
underw
urinari
antigen
test
along
clinic
evalu
defin
suspect
pathogen
penicillin
use
treatment
pneumococcu
erythromycin
atyp
pathogen
amoxicillin
clavulan
mix
infect
flucloxacillin
option
gentamicin
therapi
influenza
infect
differ
either
group
length
stay
earli
late
clinic
failur
mortal
rate
fig
howev
empir
therapi
patient
higher
mortal
admit
icu
empir
therapi
group
advers
event
may
relat
use
iv
erythromycin
rather
newer
macrolid
fewer
iv
side
effect
studi
establish
safeti
empir
therapi
test
benefit
diagnost
test
longterm
control
antibiot
use
avoid
resist
past
sever
year
new
therapi
approv
new
data
collect
agent
moxifloxacin
fluoroquinolon
use
treat
cap
inpati
trial
elderli
hospit
patient
demonstr
cardiac
safeti
equival
levofloxacin
statist
significantli
rapid
rate
clinic
improv
day
therapi
high
bioavail
quinolon
agent
may
allow
oral
therapi
replac
iv
therapi
thu
keep
patient
cap
hospit
use
oral
levofloxacin
along
clusterrandom
protocol
design
loeb
et
al
document
safeti
approach
nurs
home
patient
cap
abl
eat
drink
puls
beatsmin
respiratori
rate
breathsmin
systol
bp
mm
hg
oxygen
satur
telithromycin
first
ketolid
similar
macrolid
term
antimicrobi
spectrum
activ
macrolideresist
pneumococci
demonstr
tendenc
reduc
need
hospit
use
oral
outpati
therapi
cap
compar
clarithromycin
howev
drug
optim
activ
haemophilu
influenza
toxic
issu
see
limit
widespread
use
linezolid
also
shown
effect
drugresist
pneumococcu
consid
drug
empir
therapi
cap
sinc
use
agent
mrsa
aris
hospit
commun
concern
new
agent
defin
role
cap
manag
safeti
major
consider
quinolon
class
antibiot
gatifloxacin
recent
document
caus
hypoglycemia
hyperglycemia
limit
abil
use
safe
diabet
patient
quinolon
caus
qt
prolong
cardiac
arrhythmia
limit
use
agent
sparfloxacin
mention
random
doubleblind
compar
studi
levofloxacin
moxifloxacin
use
clinic
evalu
holter
monitor
found
differ
frequenc
clinic
signific
cardiac
event
two
agent
telithromycin
recent
associ
infrequ
case
druginduc
liver
necrosi
awar
potenti
complic
essenti
drug
use
optim
durat
therapi
cap
known
sever
recent
develop
push
shorter
durat
especi
outpati
new
formul
azithromycin
allow
administr
full
cours
therapi
singl
dose
outpati
popul
telithromycin
use
day
outpati
cap
levofloxacin
mg
effect
given
day
inpati
cap
given
day
dose
mg
recent
studi
compar
day
therapi
amoxicillin
day
therapi
hospit
patient
show
shortdur
therapi
compar
longer
durat
therapi
term
clinic
success
howev
studi
includ
patient
mildtomoder
ill
patient
elig
shortdur
therapi
condit
improv
substanti
iv
therapi
day
one
correl
find
hospit
patient
becom
clinic
stabl
iv
therapi
could
safe
discharg
hospit
without
continu
inpati
observ
recent
medicar
databas
studi
compar
cap
patient
observ
discharg
day
switch
oral
therapi
observ
day
switch
differ
readmiss
rate
mortal
rate
group
emphas
safeti
keep
patient
hospit
observ
switch
iv
therapi
adjunct
therapi
sever
cap
care
patient
sever
pneumonia
focus
earli
identif
patient
prompt
therapi
multipl
antibiot
current
guidelin
patient
recommend
monotherapi
agent
includ
quinolon
recent
random
studi
levofloxacin
monotherapi
compar
combin
therapi
cap
patient
admit
icu
support
recommend
tabl
studi
evalu
patient
admit
icu
found
monotherapi
effect
combin
therapi
person
need
mechan
ventil
sinc
trial
also
exclud
patient
septic
shock
author
conclud
monotherapi
could
recommend
cap
patient
septic
shock
receiv
mechan
ventil
condit
repres
major
individu
admit
icu
two
adjunct
therapi
activ
protein
c
system
corticosteroid
studi
patient
sever
cap
retrospect
analysi
prowess
studi
activ
protein
c
identifi
patient
studi
cap
approxim
quarter
infect
pneumococcu
patient
cap
receiv
activ
protein
c
surviv
benefit
acut
physiolog
chronic
health
evalu
apach
ii
score
pneumococc
infect
psi
class
iv
v
score
least
unclear
reason
patient
receiv
adequ
therapi
small
drop
mortal
rate
benefit
much
greater
receiv
inadequ
therapi
mortal
rate
drop
mortal
rate
reduct
day
fell
day
data
interest
suggest
benefit
expens
therapi
ideal
random
trial
patient
sever
cap
rather
subset
analysi
alon
would
convinc
addit
limit
benefit
receiv
adequ
therapi
falloff
surviv
benefit
detract
costeffect
therapi
therapi
system
corticosteroid
demonstr
use
patient
septic
shock
rel
adren
insuffici
howev
new
studi
therapi
system
corticosteroid
test
patient
sever
cap
base
idea
advers
outcom
mediat
inflammatori
respons
infect
rather
uncontrol
infect
small
patient
multicent
random
blind
trial
therapi
continu
infus
hydrocortison
compar
therapi
placebo
although
patient
sever
cap
treat
icu
steroid
therapi
led
significantli
lower
mortal
shorter
length
icu
stay
shorter
durat
mechan
ventil
addit
steroid
therapi
led
fewer
late
complic
although
data
impress
confirm
larger
studi
need
nonetheless
find
suggest
steroid
therapi
danger
even
patient
sever
infect
cap
sinc
cm
conjunct
joint
commiss
accredit
healthcar
organ
promot
standard
care
cap
patient
shown
improv
outcom
expect
hospit
meet
standard
whenev
possibl
tabl
pressur
achiev
high
complianc
rate
measur
increas
move
collect
data
complianc
publicli
report
inform
evid
support
core
measur
gener
strong
may
correct
tri
achiev
measur
patient
clinic
situat
reason
goal
may
complianc
varieti
unintend
advers
consequ
occur
rate
higher
current
evidencebas
standard
base
retrospect
databas
analysi
follow
administ
first
dose
antibiot
within
h
patient
arriv
hospit
select
one
recommend
antibiot
therapi
admit
patient
differ
choic
icu
medic
ward
make
sure
blood
cultur
perform
collect
prior
antibiot
administr
provid
smoke
cessat
advic
appropri
patient
evalu
need
offer
meet
criteria
pneumococc
influenza
vaccin
sever
area
problemat
new
data
avail
guid
clinician
recommend
administ
therapi
within
h
recommend
use
monotherapi
icuadmit
cap
valu
blood
cultur
safeti
repeat
pneumococc
vaccin
one
import
chang
applic
core
measur
recognit
patient
admit
hospit
pneumonia
healthcareassoci
pneumonia
hcap
patient
risk
infect
multidrugresist
gramneg
pathogen
mrsa
thu
need
differ
approach
therapi
usual
cap
patient
hcap
includ
guidelin
nosocomi
pneumonia
form
nosocomi
infect
thu
sinc
juli
patient
identifi
hcap
exclud
cm
core
measur
cap
antibiot
choic
justifi
data
show
hcap
differ
natur
histori
cap
bacteriolog
also
differ
cap
presum
therapi
controversi
administr
antibiot
within
h
patient
arriv
hospit
vigor
concern
even
largescal
databas
show
reduc
mortal
rate
therapi
given
time
interv
sever
unintend
consequ
follow
includ
indiscrimin
use
antibiot
patient
respiratori
symptom
emerg
depart
even
diagnosi
certain
temptat
priorit
pneumonia
patient
ahead
sick
individu
busi
emerg
depart
two
recent
studi
ad
controversi
first
studi
confirm
therapi
provid
h
mortal
reduc
predictor
increas
time
antibiot
administr
alter
mental
statu
absenc
fever
absenc
hypoxia
increas
age
factor
control
time
therapi
impact
mortal
thu
author
conclud
time
administr
antibiot
good
qualiti
measur
support
find
anoth
studi
found
medicar
patient
cap
present
atyp
clinic
featur
led
diagnost
uncertainti
could
appropri
lead
delay
administr
antibiot
editori
accompani
articl
observ
made
time
administr
antibiot
demonstr
affect
mortal
patient
year
age
find
studi
support
idea
complianc
standard
would
necessarili
mean
good
medic
care
thu
goal
lower
number
patient
given
antibiot
within
h
standard
antibiot
administr
within
h
like
chang
blood
cultur
shown
favor
alter
outcom
cap
patient
thu
argu
collect
routin
patient
admit
hospit
may
need
test
may
wise
still
collect
blood
cultur
patient
sign
sever
ill
import
collect
cultur
prior
antibiot
administr
meterski
et
al
studi
medicar
patient
cap
admit
hospit
defin
predictor
bacteremia
found
certain
popul
especi
receiv
prior
antibiot
therapi
unlik
true
posit
cultur
find
thu
larg
percentag
posit
result
patient
would
falseposit
result
could
lead
mistak
manag
predictor
bacteremia
follow
prior
antibiot
therapi
comorbid
liver
diseas
systol
bp
mm
hg
fever
puls
beatsmin
bun
level
mgdl
serum
na
level
meql
wbc
count
cellsl
cellsl
common
pathogen
found
blood
cultur
pneumococcu
pathogen
contamin
author
suggest
patient
receiv
prior
antibiot
therapi
none
severitycomorbid
risk
factor
list
blood
cultur
perform
sinc
patient
trueposit
find
bacteremia
without
prior
antibiot
therapi
predictor
prior
antibiot
therapi
one
predictor
one
blood
cultur
perform
sinc
incid
trueposit
result
final
yield
high
patient
two
predictor
bacteremia
one
predictor
prior
antibiot
therapi
bacteremia
patient
two
blood
cultur
perform
one
concern
core
measur
emphasi
pneumococc
vaccin
possibl
patient
receiv
repeat
vaccin
less
recommend
interv
absenc
reliabl
histori
vaccin
especi
patient
repeatedli
hospit
patient
treat
nurs
home
one
way
deal
vaccin
patient
uncertainti
wwwchestjournalorg
chest
april
histori
vaccin
may
justifi
proven
efficaci
vaccin
longterm
consequ
pneumonia
develop
patient
approach
use
reassur
know
gener
safe
administ
repeat
pneumococc
vaccin
frequent
recommend
interv
studi
evalu
patient
receiv
least
three
vaccin
compar
clinic
cours
patient
receiv
either
one
two
dose
even
though
patient
revaccin
receiv
repeat
vaccin
year
one
patient
advers
reaction
describ
tachycardia
arm
red
thu
appear
safe
administ
vaccin
although
done
indiscrimin
done
benefit
like
far
outweigh
associ
risk
support
recommend
give
pneumococc
vaccin
wide
find
two
recent
studi
one
studi
new
heptaval
conjug
pneumococc
vaccin
children
demonstr
benefit
reduc
invas
ill
popul
group
immun
also
adult
particularli
year
age
target
immun
effort
find
impli
vaccin
larg
segment
atrisk
popul
benefit
nonvaccin
patient
lower
incid
spread
invas
diseas
anoth
databas
studi
evalu
impact
prior
pneumococc
vaccin
patient
hospit
cap
hospit
cap
patient
receiv
prior
vaccin
group
less
like
die
caus
lower
risk
respiratori
failur
complic
well
reduc
length
hospit
stay
compar
patient
vaccin
studi
cap
past
sever
year
tackl
larg
number
import
topic
gener
direct
new
develop
discuss
review
describ
way
improv
patient
manag
patient
outcom
mani
find
incorpor
perform
measur
relat
diseas
manag
evid
base
support
recommend
strong
continu
expand
